Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial

Erstveröffentlichung

2003

Authors

Schlenk, RF

Benner, A

Hartmann, F

del Valle, F

Weber, C

et al.

Wissenschaftlicher Artikel

Published in

Leukemia ; 17 (2003), 8. - S. 1521-1528. - ISSN 0887-6924

Link to publication

https://dx.doi.org/10.1038/sj.leu.2403009

Institutions

UKU. Klinik für Innere Medizin III

Subject headings

[Free subject headings]: acute myeloid leukemia | risk-adapted postremission therapy | bone-marrow-transplantation | acute myelogenous leukemia | stem-cell transplantation | dose cytosine-arabinoside | study-group ulm | prognostic-significance | intensive chemotherapy | normal cytogenetics | myelodysplastic syndrome | progenitor cells
[DDC subject group]: DDC 610 / Medicine & health

Metadata

Show full item record